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Abstract
Background: The role of different chemokine receptors in the pathogenesis of multiple sclerosis (MS) has been
extensively investigated; however, little is known about the difference in the role of chemokine receptors between
the pathogenesis of neuromyelitis optica (NMO) and MS. Therefore, we examined the expression of chemokine
receptors on peripheral blood lymphocytes (PBL) in MS and NMO.
Methods: We used flow cytometry to analyse lymphocyte subsets in 12 patients with relapsing NMO, 24 with
relapsing-remitting MS during relapse, 3 with NMO and 5 with MS during remission.
Results: Compared with healthy controls (HC), the percentage of lymphocytes in white blood cells was significantly
lower in NMO and MS patients. The percentage of T cells expressing CD4
+CD25
+ and CD4
+CD45RO
+ was higher, while
that of CD4
+CC chemokine receptor (CCR)3
+ (T helper 2, Th2) was significantly lower in MS patients than in HC. The
ratios of CD4
+CXC chemokine receptors (CXCR)3
+/CD4
+CCR3
+ (Th1/Th2) and CD8
+CXCR3
+/CD8
+CCR4
+ (T cytotoxic 1,
Tc1/Tc2) were higher in MS patients than in HC. The percentage of CD8
+CXCR3
+ T cell (Tc1) and CD4
+CXCR3
+ Tc e l l
(Th1) decreased significantly during remission in MS patients (P< 0.05). No significant differences were identified in the
expression of the chemokine receptors on PBL in NMO patients compared with MS patients and HC.
Conclusions: Th1 dominance of chemokine receptors on blood T cells and the correlation between CXCR3
+ T cell
(Th1 and Tc1) and disease activity in MS patients were confirmed by analysing chemokines receptors on PBL. In
contrast, deviation in the Th1/Th2 balance was not observed in NMO patients.
Background
Chemokines attract various types of leukocytes to sites
of infection and inflammation and act as immunoregula-
tory molecules in driving T-helper (Th)1/Th2 responses
[1]. The role of different chemokines and chemokine
receptors in the pathogenesis of multiple sclerosis (MS)
has been extensively investigated [2-5]; however, little is
known about the role of chemokine receptors in the
pathogenesis of neuromyelitis optica (NMO).
NMO is an immune-mediated inflammatory disorder of
the central nervous system and predominantly affects the
optic nerves and spinal cord [6]. Recent evidences such as
the discovery of serum anti-aquaporin-4 (AQP4) antibody
in NMO patients [7] (now recognised as a specific
biomarker for NMO), differences in pathology [8], neuroi-
maging [9], cytokine profiles [10,11] and responses to
some immunotherapies between MS and NMO [12], sup-
ports the hypothesis that NMO is distinct from MS.
In the present study, we report the expression of che-
mokine receptors on peripheral blood lymphocytes
(PBL) in NMO and MS during relapse compared with
healthy controls (HC) to determine differences in the
expression of chemokine receptors between these
disorders.
Methods
Patients
This study included 12 Japanese patients with relapsing
NMO fulfilling Wingerchuk’s revised criteria [6] that
uses seropositivity of the anti-AQP4 antibody [13]
instead of NMO-IgG. In addition, the study included
24 patients with relapsing-remitting MS fulfilling
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were obtained during relapse, which was defined as the
period within one month of clinical relapse and before
beginning relapse treatment. Blood samples from 25
healthy participants (9 women and 16 men; mean age,
32.7 years) served as controls. In addition, blood sam-
ples during remission were obtained from only 3 of the
12 NMO patients and 5 of the 24 MS patients.
We also reviewed the clinical characteristics of NMO
and MS patients such as gender, age, disease duration,
expanded disability status scale (EDSS) and the propor-
tion of patients receiving immunomodulating treatment.
Ethics approval was granted by the Ethics Committee
of Chiba University School of Medicine, Chiba, Japan.
All study subjects gave informed consent for their
participation.
Flow cytometry
Blood samples collected in heparinised tubes were
washed with phosphate buffered saline (PBS), supple-
mented with 0.5% foetal calf serum and resuspended in
PBS with 0.5% foetal calf serum. Subsequently, the ali-
quots of the cell suspensions were double-stained with
fluorescein isothiocyanate- and phycoerythrin-labelled
monoclonal antibodies for 30 min at 4°C in the dark.
Table 1 summarises the combinations of monoclonal
antibodies used to identify chemokine receptor-positive
cells as well as for other lymphocyte subsets. After lysing
the red blood cells with FACS Lysing Solution (BD Bio-
sciences, San Jose, CA, USA.), the cells were washed with
PBS and resuspended in 0.5 ml PBS. IgG1 coupled to
fluorescein isothiocyanate and IgG2a coupled to phycoer-
ythrin were used as negative controls. The percentages of
chemokine receptor-positive cells or lymphocyte subsets
were obtained using a FACScan (BD Biosciences).
Statistical analysis
For baseline variables, the groups were compared using
Fisher’s exact test for categorical outcomes, the Mann-
Whitney U test for continuous variables and paired
t-test for paired continuous measures. All comparisons
were planned, tests were two-sided and P values < 0.05
were considered to be statistically significant. In addi-
tion, multiple testing problems were resolved by apply-
ing the Bonferroni correction on the computed P values
to reduce type I errors. All statistical analyses were per-
formed using SPSS 16.0J (SPSS Japan Inc., Tokyo,
Japan).
Results
Clinical characteristics of NMO and MS patients
Clinical characteristics of 12 NMO and 24 MS patients
are as described below. The proportion of female patients
(NMO, men:women = 0:12; MS, men:women = 5:19; P =
0.11), age (NMO, 48.3 ± 13.8 years old [mean ± SD]; MS,
33.9 ± 10.0; P = 0.04) and EDSS (NMO, 8.0 [range 2.0-
9.0]; MS, 3.0 [1.5-7.5]; P < 0.001) at the blood sampling
w e r eh i g h e ri nN M Ot h a ni nM Sp a t i e n t s .T h ep r o p o r -
tion of patients who received immunomodulating therapy
was not statistically different between NMO and MS
patients (33% in NMO, 1 patient with interferon beta and
3 with oral prednisolone; 21% in MS, 4 patients with
interferon beta and 1 with oral prednisolone).
Lymphocytes subsets in NMO and MS patients
White blood cell (WBC) counts were 7352 ± 732/μl
(mean ± SE), 7492 ± 513 and 5864 ± 274 in MS
patients, NMO patients and HC, respectively. WBC
counts were significantlye l e v a t e di nN M Oa n dM S
patients than in HC. Compared to HC, the percentage
of lymphocytes was significantly lower in both NMO
and MS patients. The percentage of T cells expressing
CD4
+CD25
+ and CD4
+CD45RO
+ was significantly
higher, while the percentage of T cells expressing
CD4
+CC chemokine receptor (CCR)3
+ (Th2 cells)
was significantly lower in MS patients than in HC.
The ratios of CD4
+ CXC chemokine receptors (CXCR)
3
+/CD4
+CCR3
+ indicating Th1/Th2 and CD8
+CXCR3
+/
CD8
+CCR4
+ indicating cytotoxic T (Tc) 1/Tc2 was sig-
nificantly higher only in MS patients. Although not sta-
tistically significant after applying the Bonferroni
correction, the percentages of CD4
+CXCR3
+ T cells
(Th1 cells; P = 0.039), CD8
+CXCR3
+ T cells (Tc1 cells;
P = 0.020) and the ratio of CD4
+CXCR3
+/CD4
+CCR4
+
indicating Th1/Th2 (P = 0.023) tended to be higher in
MS patients compared with HC. CD8
+CCR4
+ T cells
(Tc2 cells; P = 0.017) and the ratio of CD4
+CCR5
+/-
CD4
+CCR4
+ indicating Th1/Th2 (P =0 . 0 4 1 )t e n d e dt o
b el o w e ri nM Sp a t i e n t st h a ni nH C( T a b l e2 ) .A f t e r
applying the Bonferroni correction, NMO patients did
not show any significant differences in the expression of
the chemokine receptors on PBL compared with MS
patients and HC. The analysis of patients between the
relapse and remission phases revealed significantly
Table 1 Combinations of monoclonal antibodies used
Chemokine receptor-positive cells Other lymphocyte subsets
FITC-labelled PE-labelled FITC-labelled PE-labelled
CCR3
c × CD4
b CD3
a × CD19
a
CD4
b × CCR4
a CD3
a × CD4
a
CCR5
c ×CD4
b CD3
a × CD8
a
CXCR3
c × CD4
b CD4
b × CD25
a
CD8
b × CCR4
a CD45RA
a × CD4
b
CXCR3
c × CD8
b CD4
b × CD45RO
a
Monoclonal antibodies were purchased from
aBD Biosciences, San Jose, CA,
USA,
bBeckman Coulter, Marseille, France, or
CDako Japan, Kyoto, Japan,
FITC = fluorescein isothiocyanate; PE = phycoerythrin; CCR = CC chemokine
receptor; CXCR = CXC chemokine receptor.
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Page 2 of 5decreased percentages of CD4
+CXCR3
+ Th1 cells (P =
0.038) and CD8
+CXCR3
+ Tc1 cells (P = 0.023) at the
remission phase in all 5 MS patients (Figure 1). None of
the lymphocyte subsets were correlated with clinical
parameters such as EDSS, disease duration or anti-
AQP4 antibody titre.
Discussion
In this study, we analysed the expression of chemokine
receptors on circulating PBL during relapse in NMO
and MS patients and compare it with that of HC. We
confirmed the dominance of the Th1- and Tc1-related
chemokine receptors in MS patients; however, no
remarkable differences were observed between NMO
and HC patients.
Th1 and Th2 subsets of lymphocytes can be charac-
terised by their expression of chemokine receptors.
CXCR3 and CCR5 are associated with a Th1 phenotype,
whereas CCR3 and CCR4 are expressed preferentially on
activated Th2 cells [15]. Several studies have reported
Th1 dominance over the Th2 response associated with
chemokine receptors in MS, increased percentages of T
cells expressing CXCR3 and CCR5 chemokine receptors
on PBL and cerebrospinal fluid (CSF) in the active phase
of MS and the identification of CXCR3
+ and CCR5
+ T
cells in active demyelinating MS brain lesions [2,3]. Th1
dominance over the Th2 response is also indicated by
decreased expression of the chemokine receptor CCR4
on blood T cells and brain tissue [4,5]. The results of our
study indicates higher expression of Th1-associated che-
mokine receptors CD4
+CXCR3
+ on peripheral T cells
and lower expression of Th2-associated chemokine
Table 2 Lymphocyte subsets (%) on blood of patients with NMO and MS
PB measurements (%) Lymphocyte subsets NMO (n = 12) MS (n = 24) NC (n = 25) P value
NMO vs NC MS vs NC NMO vs MS
Lymphocyte 18.8 ± 1.8 25.7 ± 2.0 35.4 ± 1.8 <0.001* 0.001* 0.009*
CD3+ T cell 73.5 ± 2.6 70.2 ± 1.7 66.1 ± 1.7 0.039 0.071 0.486
CD3+CD4+ Th/Ti 40.8 ± 2.9 41.6 ± 2.2 38.8 ± 1.3 0.212 0.045 0.837
CD3+CD8+ Ts/Tc 31.5 ± 2.7 28.4 ± 1.7 26.4 ± 1.4 0.205 0.321 0.767
CD3+CD19+ B cell 15.4 ± 2.0 17.0 ± 1.2 17.3 ± 0.9 0.527 0.810 0.600
CD4+CD25+ 16.8 ± 2.3 17.0 ± 1.4 11.4 ± 0.9 0.051 <0.001* 0.674
CD4+CD45RO+ Memory T 28.0 ± 2.4 27.1 ± 1.6 23.0 ± 0.9 0.039 0.007* 0.810
CD4+CD45RA+ Naïve T 22.9 ± 2.7 26.9 ± 2.0 25.8 ± 1.5 0.427 0.656 0.289
CD4+CXCR3+ Th1 23.9 ± 3.5 24.9 ± 2.4 19.6 ± 1.9 0.188 0.039 0.722
CD4+CCR5+ Th1 0.7 ± 0.2 1.0 ± 0.3 1.4 ± 0.3 0.112 0.062 0.730
CD4+CCR4+ Th2 25.2 ± 2.1 26.9 ± 1.9 26.4 ± 1.4 0.602 0.785 0.470
CD4+CCR3+ Th2 1.1 ± 0.2 0.9 ± 0.2 1.8 ± 0.2 0.022 0.001* 0.272
CD8+CXCR3+ Tc1 21.1 ± 4.1 18.3 ± 1.0 15.4 ± 1.9 0.183 0.020 0.844
CD8+CCR4+ Tc2 9.5 ± 2.4 6.9 ± 0.7 9.6 ± 0.9 0.355 0.017 0.952
CD4+CXCR3+/CD4+CCR4+ Th1/2 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 0.122 0.023 0.908
CD4+CXCR3+/CD4+CCR3+ Th1/2 31.4 ± 9.4 23.1 ± 2.4 13.7 ± 1.9 0.035 0.007* 0.966
CD4+CCR5+/CD4+CCR4+ Th1/2 0.03 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.093 0.041 0.646
CD4+CCR5+/CD4+CCR3+ Th1/2 0.7 ± 0.2 1.2 ± 0.3 0.8 ± 0.1 0.520 0.754 0.453
CD8+CXCR3+/CD8+CCR4+ Tc1/2 3.4 ± 0.6 3.4 ± 0.5 2.0 ± 0.3 0.056 <0.001* 0.738
Values indicate mean ± standard error, PB: peripheral blood, NMO: neuromyelitis optica, MS: multiple sclerosis, HC: healthy control, Th: helper Tcell, Ti: inducer T,
Ts: suppressor T, Tc: cytotoxic T, CCR: CC chemokine receptor, CXCR: CXC chemokine receptor. *Statistically significantly even after multiple comparison
adjustment.
Figure 1 Sequential data of CXCR3
+ T cells in MS patients.T h e
percentages of CD8
+CXCR3
+ T cells (cytotoxic T type1 cells) and
CD4
+CXCR3
+ T cells (helper T type 1 cells) at the relapse and
remission phase in 5 MS patients. Both percentages of CD8
+CXCR3
+
and CD4
+CXCR3
+ T cell decreased at remission phase in all 5 MS
patients (P = 0.023 and 0.038).
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+CCR3
+ in MS patients than in
HC, which is in accordance with the results of the above-
mentioned reports. Ratios of CD4
+CXCR3
+/CD4
+CCR4
+
and CD4
+CXCR3
+/CD4
+CCR3
+ were higher in MS
patients than HC, which also indicates Th1 dominance in
balancing Th1/Th2 responses. Furthermore, we con-
firmed higher percentages of peripheral CD4
+CD25
+
(regulatory or activated T cells) and CD4
+CD45RO
+T
cells (memory T cells) in MS patients than in HC, which
is in accordance with previous studies [16,17].
Our results estimated that the ratios of CD8
+CXCR3
+/
CD8
+CCR4
+, indicating Tc1/Tc2, were significantly higher
in MS patients than in HC. In addition, the percentage of
CD4
+CXCR3
+ and CD8
+CXCR3
+ T cells was correlated
with disease activity in MS. The roles and functions of che-
mokine receptors on CD8
+ T cells remain to be elucidated.
CD8
+CXCR3
+ T cells are associated with migration and
differentiation of memory T cells [18] and also have a simi-
lar function as regulatory T cells (Treg) [19]. Our results
indicate Tc1 dominance over Tc2 in MS, which may reflect
the abnormality of Treg in MS.
To the best of our knowledge, no studies have
reported the expression of chemokine receptors on PBL
in NMO patients. A few studies have investigated che-
mokine levels in NMO, in which CXCL10/IP-10 and
CCL17/TARC levels were significantly elevated in NMO
patients [20] and CXCL-8/IL-8, CCL4/MIP-1b and
CCL2/MCP-1 levels showed significant elevation in opti-
cospinal MS patients (part of them are considered
NMO) compared with normal subjects [10].
Recent studies have shown that anti-AQP4 antibody
and complements play a critical role of in the pathogen-
esis of NMO [21]. Thus, we expected the up-regulated
expression of Th2-related chemokine receptors in
NMO; however, no remarkable deviation in the Th1/
Th2 balance was observed in this study. Recent studies
have revealed that Th17-related cytokines and chemo-
kines play a dominant role in the pathogenesis of NMO
from elevated protein levels of IL-17 and IL-8 in the
CSF of opticospinal MS patients [10] and IL-6 in the
CSF of NMO patients [11]. Th17 cells belong to a dis-
tinct lineage of Th1 and Th2 cells, which are responsible
for organ-specific autoimmune diseases. Although the
association between Th17 cells and NMO remains
unclear, Th17 related-responses may be more important
than Th1-and Th2-related responses in NMO pathogen-
esis. Hence, no remarkable changes might be seen in
the Th1/Th2-related chemokine receptors on peripheral
T cells. However, our study has a limitation because the
subject was chemokine receptors on only PBL, and not
on CSF, and thus we were unable elucidate the complete
Th1/Th2 balance in the pathogenesis of MS and NMO.
In this study, some patients received oral prednisolone
treatment. It has been reported that high-dose
intravenous methylprednisolone reduced CD4
+CXCR3
+
Th1 cells [17] and CCR5
+ Th1 cells in MS patients [22].
Hence, it can be suggested that steroid treatment
affected the expression of chemokine receptors in this
study. However, only one (4%) patient with MS and
three (25%) with NMO received oral prednisolone at
sampling PBL, and no statistical difference was found
between the percentage of patients treated with steroid
in NMO and MS. We hypothesise that steroid treatment
had a relatively small effect on the results. Meanwhile,
higher WBC counts and lower lymphocyte percentages
in NMO and MS patients were possibly affected by
immunomodulating therapy.
Conclusions
In conclusion, we have identified several differences,
such as Th1 and Tc1 dominance and the association
between CXCR3
+ (Th1 and Tc1) and disease activity in
T cell subsets on PBL, in MS patients compared with
HC, but these differences did not appear in NMO
patients. We cannot determine characteristic lympho-
cyte subsets on PBL involved in the pathophysiology of
NMO. Although further studies will be required to
determine the immunological features of NMO, these
differences in PBL could be based on immunological dif-
ferences between NMO and MS.
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